FR3127700B1 - Système pour la libération d’un hémostatique dans la cavité utérine - Google Patents

Système pour la libération d’un hémostatique dans la cavité utérine Download PDF

Info

Publication number
FR3127700B1
FR3127700B1 FR2110541A FR2110541A FR3127700B1 FR 3127700 B1 FR3127700 B1 FR 3127700B1 FR 2110541 A FR2110541 A FR 2110541A FR 2110541 A FR2110541 A FR 2110541A FR 3127700 B1 FR3127700 B1 FR 3127700B1
Authority
FR
France
Prior art keywords
hemostatic agent
uterine cavity
release
degradable
block
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2110541A
Other languages
English (en)
Other versions
FR3127700A1 (fr
Inventor
Xavier Garric
Gonzague Issenmann
Elodie Gatouillat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Womed
Centre National de la Recherche Scientifique CNRS
Ecole Nationale Superieure de Chimie de Montpellier ENSCM
Universite de Montpellier
Original Assignee
Womed
Centre National de la Recherche Scientifique CNRS
Ecole Nationale Superieure de Chimie de Montpellier ENSCM
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Womed, Centre National de la Recherche Scientifique CNRS, Ecole Nationale Superieure de Chimie de Montpellier ENSCM, Universite de Montpellier filed Critical Womed
Priority to FR2110541A priority Critical patent/FR3127700B1/fr
Priority to US18/698,799 priority patent/US20250000789A1/en
Priority to PCT/EP2022/077602 priority patent/WO2023057460A1/fr
Priority to EP22800623.5A priority patent/EP4412585A1/fr
Publication of FR3127700A1 publication Critical patent/FR3127700A1/fr
Application granted granted Critical
Publication of FR3127700B1 publication Critical patent/FR3127700B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

L’invention a pour objet un système intra-utérin dégradable pour la libération d’un hémostatique dans la cavité utérine comprenant  une matrice polymérique dégradable à base de copolymères comprenant au moins un copolymère blocs A et B, et un hémostatique destiné à être libéré dans la cavité utérine, dans lequel : le bloc A est un polyester ; le bloc B est un poly(oxyéthylène) (PEO) ; la masse moléculaire en poids des blocs B est supérieure ou égale à 50 kDa ; et le ratio molaire motif éthylène oxyde/motif ester est compris entre 0,5 et 5 . L’invention concerne également un hémostatique pour son utilisation dans le traitement d’une hémorragie utérine, dans lequel l’hémostatique est délivré dans la cavité intra-utérine au moyen d’un système intra-utérin dégradable selon l’invention.
FR2110541A 2021-10-05 2021-10-05 Système pour la libération d’un hémostatique dans la cavité utérine Active FR3127700B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR2110541A FR3127700B1 (fr) 2021-10-05 2021-10-05 Système pour la libération d’un hémostatique dans la cavité utérine
US18/698,799 US20250000789A1 (en) 2021-10-05 2022-10-04 System for releasing a haemostatic agent into the uterine cavity
PCT/EP2022/077602 WO2023057460A1 (fr) 2021-10-05 2022-10-04 Système de libération d'un agent hémostatique dans la cavité utérine
EP22800623.5A EP4412585A1 (fr) 2021-10-05 2022-10-04 Système de libération d'un agent hémostatique dans la cavité utérine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2110541 2021-10-05
FR2110541A FR3127700B1 (fr) 2021-10-05 2021-10-05 Système pour la libération d’un hémostatique dans la cavité utérine

Publications (2)

Publication Number Publication Date
FR3127700A1 FR3127700A1 (fr) 2023-04-07
FR3127700B1 true FR3127700B1 (fr) 2024-07-26

Family

ID=80735722

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2110541A Active FR3127700B1 (fr) 2021-10-05 2021-10-05 Système pour la libération d’un hémostatique dans la cavité utérine

Country Status (4)

Country Link
US (1) US20250000789A1 (fr)
EP (1) EP4412585A1 (fr)
FR (1) FR3127700B1 (fr)
WO (1) WO2023057460A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6605294B2 (en) * 1998-08-14 2003-08-12 Incept Llc Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
WO2012121811A1 (fr) * 2011-03-04 2012-09-13 Arstat, Inc. Traitement des pertes de sang menstruelles excessives par administration intravaginale de faibles doses d'un agent antifibrinolytique ou hémostatique
FR3024455B1 (fr) * 2014-08-04 2018-03-02 Ecole Nationale Superieure De Chimie De Montpellier Composition de copolymeres diblocs et triblocs et son utilisation dans la prevention des adherences tissulaires
US20170326072A1 (en) * 2016-04-29 2017-11-16 i-novion, Inc. Sustained Release Formulation and Use Thereof

Also Published As

Publication number Publication date
WO2023057460A1 (fr) 2023-04-13
FR3127700A1 (fr) 2023-04-07
US20250000789A1 (en) 2025-01-02
EP4412585A1 (fr) 2024-08-14

Similar Documents

Publication Publication Date Title
Myung et al. Progress in the development of interpenetrating polymer network hydrogels
CA2403218A1 (fr) Compositions anti-embolie
CN101171531B (zh) 用于持续递送活性化合物的眼科器件
AU2011234637B2 (en) A fast dissolving pharmaceutical composition
ES2620090T3 (es) Composición de elastómero termoplástico y cuerpo moldeado
Sarris et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia [see comments]
BR0108150A (pt) Copolìmeros de impacto de propileno
JP2003528183A5 (fr)
FR3127700B1 (fr) Système pour la libération d’un hémostatique dans la cavité utérine
IL110787A0 (en) Biodegradable polymer, its preparation and pharmaceutical composition containing it
DE69826882D1 (de) Bioresorbierbare zusammensetzungen für implantierfähige prothesen
Bagrodia et al. New polyisobutylene-based model ionomers: 5. The effect of molecular weight on the mechanical properties of tri-arm-star polyisobutylene-based model ionomers
CA2336149A1 (fr) Membrane ou matrice permettant de reguler la vitesse de permeation des medicaments
EP2357206A3 (fr) Composition catalytique comprenant un agent d'échange réversible pour la formation d'un copolymère d'éthylène
FR3024455B1 (fr) Composition de copolymeres diblocs et triblocs et son utilisation dans la prevention des adherences tissulaires
JP2016089099A (ja) 非共有結合性エラストマー
FR3127699B1 (fr) Système intra-utérin dégradable pour la libération prolongée d’un principe actif dans la cavité utérine
JP3832970B2 (ja) 温度応答型生体内分解性高分子
MX2021015901A (es) Composiciones oftalmicas.
Nazhat et al. Isoprene–styrene copolymer elastomer and tetrahydrofurfuryl methacrylate mixtures for soft prosthetic applications
Mišković et al. Association of angiotensin-converting enzyme insertion-deletion polymorphism with preeclampsia
Nazhat et al. Blends of isoprene–styrene/methacrylate monomer systems as denture soft lining material
ES2225100T3 (es) Proceso para producir copolimeros de bloques en disminucion.
US6620900B2 (en) Proliferous copolymer of vinyl pyrrolidone and vinyl acetate
Müller et al. Safety, efficacy and quality of life of the novel vaginal contraceptive ring containing etonogestrel/ethinylestradiol 11.0/3.474 mg after 3 years of “real life” experience.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20230407

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5